Gencurix Inc.

KOSDAQ 229000.KQ

Gencurix Inc. Capital Expenditure for the year ending December 31, 2023: USD -1.67 M

Gencurix Inc. Capital Expenditure is USD -1.67 M for the year ending December 31, 2023, a 83.78% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • Gencurix Inc. Capital Expenditure for the year ending December 31, 2022 was USD -10.31 M, a -737.14% change year over year.
  • Gencurix Inc. Capital Expenditure for the year ending December 31, 2021 was USD -1.23 M, a -2.12% change year over year.
  • Gencurix Inc. Capital Expenditure for the year ending December 31, 2020 was USD -1.21 M, a -21.37% change year over year.
  • Gencurix Inc. Capital Expenditure for the year ending December 31, 2019 was USD -993.35 K, a -78.69% change year over year.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
SV Wall Street
KOSDAQ: 229000.KQ

Gencurix Inc.

CEO Sung-Rai Cho
IPO Date April 5, 2017
Location South Korea
Headquarters Hanhwa Bizmetro
Employees 69
Sector Healthcare
Industries
Biotechnology Clinical Trials Medical Instruments Pharmaceuticals Vaccines
Description

Gencurix Inc. provide diagnostic solutions in South Korea. Its products include GenesWell BCT, a prognosis diagnostic test for breast cancer; GenesWell ddEGFR Mutation Test, a companion test for lung cancer; Droplex, a genetic test that detects DNA mutations; eDX, an early diagnosis for cancer with liquid biopsy; GenePro COVID-19 detection test; GenePro SARS-CoV-2 Test kit; GenoCTC (circulating tumor cell isolator); GenePro LAMP test solution for rapid, convenient and simple detection of various infectious diseases; and GenePro LAMP Cycler, a device for loop-mediated isothermal amplification. The company was founded in 2011 and is headquartered in Seoul, South Korea.

StockViz Staff

February 5, 2025

Any question? Send us an email